Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114)

Next Previous
Search
Trial Profile

Open-Label Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary) ; Risperidone (Primary)
  • Indications Autistic disorder; Bipolar disorders; Schizophrenia
  • Focus Adverse reactions; First in man
  • Sponsors Delpor

Most Recent Events

  • 20 Nov 2019 Planned number of patients changed from 14 to 17.
  • 20 Nov 2019 Status changed from recruiting to completed.
  • 11 Dec 2018 Planned End Date changed from 28 May 2018 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top